Genmab A/S (GMAB) Stock Forecast
GMAB analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 12 analysts
- Price target
- $44.40 average of analyst targets
- Upside to target
- +20.0% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $0.37
- 52-week range
- $23.85 – $38.48
GMAB analyst ratings
12 analystsNumber of analysts at each rating.
GMAB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
GMAB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.32 | $0.24 | $0.41 | $0.65 | −49.9% | 5 |
| Current fiscal year (2026) | $1.17 | $1.17 | $1.17 | $1.77 | −34.0% | 1 |
| Next fiscal year (2027) | $1.51 | $1.51 | $1.52 | $1.17 | +29.5% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
GMAB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $8.01B | $7.68B | $8.31B | +21.1% | 11 |
| Current fiscal year (2026) | $29.72B | $28.05B | $31.54B | +26.5% | 18 |
| Next fiscal year (2027) | $35.02B | $31.16B | $40.03B | +17.8% | 20 |
GMAB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
GMAB revenue: reported and forecast
GMAB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.33 | $0.35 | $0.34 | $0.33 | $0.32 | −2.1% | 1 up · 1 down |
| Current fiscal year (2026) | $0.00 | $1.13 | $1.13 | $1.18 | $1.17 | — | 1 up · 0 down |
| Next fiscal year (2027) | $0.00 | $1.59 | $1.59 | $1.53 | $1.51 | — | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
GMAB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; GMAB beat in 8 of 12.
What analysts expect from GMAB
12 analysts cover Genmab A/S; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $44.40, 20.0% above the latest close of $37.00. Analysts expect earnings of $1.17 per share for 2026, −34.0% from a year earlier. For 2027 the average estimate is $1.51 per share on revenue of $35.0 billion. Genmab A/S beat the EPS estimate in 8 of the last 12 quarters.
Related: GMAB income statement, GMAB chart. See the GMAB stock overview for the latest quote and news.
GMAB forecast FAQ
What is Genmab A/S's price target?
The average analyst price target for Genmab A/S is $44.40, 20.0% above the latest close of $37.00.
Is Genmab A/S a buy, hold or sell?
Of 12 analysts covering Genmab A/S, 10 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Genmab A/S's EPS forecast?
Analysts forecast $1.17 per share for 2026 (range $1.17 to $1.17); for 2027 the estimate is $1.51.
What is Genmab A/S's revenue forecast?
The average revenue estimate for 2026 is $29.7 billion, growth of 26.5%; for 2027 it is $35.0 billion.
When does Genmab A/S report earnings?
Genmab A/S is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $0.37.
Does Genmab A/S usually beat earnings estimates?
Genmab A/S reported EPS at or above the analyst estimate in 8 of the last 12 quarters.